Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)”

76 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 76 results

Early research (Phase 1)Study completedNCT02826772
What this trial is testing

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Suzhou Kintor Pharmaceutical Inc, 40
Testing effectiveness (Phase 2)Study completedNCT01487863
What this trial is testing

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticHormone Refractory Prostate CancerCastration-resistant Prostate Cancer
Dendreon 69
Early research (Phase 1)Study completedNCT01692262
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),Efficacy,Safety and Tolerability,+3 more
AstraZeneca 59
Testing effectiveness (Phase 2)Study completedNCT01549951
What this trial is testing

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 50
Not applicableStudy completedNCT04516161
What this trial is testing

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Bayer 1,180
Very early researchNot Yet RecruitingNCT06546527
What this trial is testing

Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）

Who this might be right for
Prostate Cancer
Peking University First Hospital 12
Testing effectiveness (Phase 2)Study completedNCT03098836
What this trial is testing

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Daniel George, MD 93
Large-scale testing (Phase 3)Looking for participantsNCT06629779
What this trial is testing

Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Pfizer 900
Post-approval studies (Phase 4)Active Not RecruitingNCT04597125
What this trial is testing

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer 654
Testing effectiveness (Phase 2)Looking for participantsNCT06785636
What this trial is testing

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Who this might be right for
mCRPC (Metastatic Castration-resistant Prostate Cancer)Prostate Cancer
Pathos AI, Inc. 120
Early research (Phase 1)Looking for participantsNCT03460977
What this trial is testing

Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)
Pfizer 453
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05570994
What this trial is testing

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Who this might be right for
Metastatic Castration-resistant Prostate CancerProstate Cancer MetastaticCastrate Resistant Prostate Cancer
British Columbia Cancer Agency 50
Testing effectiveness (Phase 2)Study completedNCT04495179
What this trial is testing

AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Who this might be right for
Progressive Metastatic Castrate-Resistant Prostate Cancer
AstraZeneca 30
Testing effectiveness (Phase 2)Ended earlyNCT01681433
What this trial is testing

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Who this might be right for
Prostate CancerMetastatic Castrate-Resistant Prostate CancerPSA
Costantine Albany 72
Not applicableStudy completedNCT04281147
What this trial is testing

Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body

Who this might be right for
Prostate Cancer
Bayer 4,301
Testing effectiveness (Phase 2)Ended earlyNCT01385293
What this trial is testing

BKM120 in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic (Spread to Other Areas of the Body)
Andrew J. Armstrong, MD 30
Testing effectiveness (Phase 2)Study completedNCT03179410
What this trial is testing

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Who this might be right for
Prostate Cancer
Andrew J. Armstrong, MD 15
Early research (Phase 1)Study completedNCT01823978
What this trial is testing

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Who this might be right for
Castrate Resistent Prostate Cancer
Bellicum Pharmaceuticals 19
Large-scale testing (Phase 3)Ended earlyNCT02057666
What this trial is testing

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Ipsen 146
Testing effectiveness (Phase 2)Looking for participantsNCT04071236
What this trial is testing

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Who this might be right for
Metastatic Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+1 more
National Cancer Institute (NCI)
Load More Results
90